Nanobiotix S.A.
For the period ended Jun 30, 2026. Filed Sep 24, 2026.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Jun 30, 2026 · Filed Sep 24, 2026
Use the contents to explore the available documents and sections.
Contents
Cover page
Show cover page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Date of report: September 24, 2026
Commission File Number:001-39777
NANOBIOTIX S.A.
(Exact name of registrant as specified in its charter)
Nanobiotix S.A.
60 rue de Wattignies
75012 Paris, France
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
| ☒ Form 20-F | ☐ Form 40-F |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
This Form 6-K, including Exhibits 99.1 and 101, shall be deemed to be incorporated by reference in the registration statements of Nanobiotix on Form F-3 (File No. 333-285604 including its outstanding May 2026 prospectus supplement) and Form S-8 (File Nos. 333-296586, 333-253062, 333-257239, 333-272947 and 333-287272).
Our Half-Year Report, filed as Exhibit 99.1 hereto, includes references to the Company’s website athttp://www.nanobiotix.com. Such reference to the Company’s website is an inactive textual reference only, and the information contained in, or that can be accessed through, the Company’s website, including the Company’s universal registration document filed with the French Financial Markets Authority (Autorité des Marchés Financiers – the AMF), is not filed as a part of this Form 6-K.
EXHIBIT INDEX
| Exhibit | Description |
| 99.1 | Half-Year Financial Report From January 1, 2026 to June 30, 2026 |
| 101 | The following materials from Exhibit 99.1 (Nanobiotix S.A.’s Half-Year Financial Report From January 1, 2026 to June 30, 2026) filed on this on Form 6-K formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the unaudited interim condensed statements of consolidated financial position, (ii) the unaudited interim condensed statements of consolidated operations, (iii) the unaudited interim condensed statements of consolidated comprehensive loss, (iv) the unaudited interim condensed statements of consolidated changes in shareholders’ equity, (v) the unaudited interim condensed statements of consolidated cash flows, and (vi) the notes to the unaudited interim condensed financial consolidated statements. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| NANOBIOTIX S.A. | |
|---|---|
| /s/ LAURENT LEVY | |
| By: | Laurent Levy, Ph.D. |
| Title: | Chairman of the Executive Board |
Date: September 24, 2026
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.